Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2024-01-04 Regulatory Filings
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Informacja o warunkowej decyzji Urzędu Patentów i Znaków Towarowych Stanów Zjednoczonych o przyznaniu patentu w ramach projektu BacterOMIC - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is a short announcement from the Management Board (Zarząd) of Scope Fluidics regarding a conditional decision by the United States Patent and Trademark Office (USPTO) to grant a patent to its subsidiary, Bacteromic. The text details the subject of the patent (microfluidic chip), the condition for granting (payment of fees by April 3, 2024), and the implications of the patent (exclusivity in the US). This content relates to intellectual property rights and legal/regulatory outcomes concerning the company's technology. Since there is no specific category for 'Patent Grant Notification' and the document is short and reports a specific legal/regulatory event, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory disclosure of a significant legal development, or potentially 'Legal Proceedings Report' (LTR) if interpreted broadly as a legal outcome, but RNS is the safer general regulatory disclosure fallback. Given the focus on a patent grant, which is a specific legal/IP event, and the short nature of the filing (suggesting it's an announcement rather than a full legal report), RNS is the most appropriate general regulatory disclosure code.
2024-01-04 Polish
Rozpoczęcie testów systemu BacterOMIC w ramach Programu Early Access - Content (PL)
Legal Proceedings Report Classification · 1% confidence The document text is a formal announcement in Polish, referencing a previous report ('raport bieżący nr 15/2023') and detailing the achievement of a specific milestone ('Rozpoczęcie testów systemu BacterOMIC w ramach Programu Early Access'). It discusses operational progress, collaborations, and internal production setup related to a product (BacterOMIC system). This type of update, focusing on operational achievements, progress against strategic goals, or significant business developments that are not standard financial results (ER/IR) or management changes (MANG), often falls under general regulatory announcements. Since it is a specific update on business progress and not a standard financial report, a legal matter, or a director dealing, the most appropriate general category for a specific, non-standard regulatory update is 'Regulatory Filings' (RNS). The document length (1745 chars) is short, but it is reporting an event, not announcing the publication of a separate, larger report, so RPA is less suitable than RNS for this specific operational milestone update.
2023-12-21 Polish
Informacja o decyzji Urzędu Patentów i Znaków Towarowych Stanów Zjednoczonych o przyznaniu patentu na metodę i system do ultraszybkich oznaczeń lekooporności - Content (PL)
Regulatory Filings Classification · 1% confidence The document text, written in Polish, discusses a significant legal/intellectual property event: the US Patent and Trademark Office issuing a conditional decision to grant a patent for a method related to antimicrobial susceptibility testing. This directly relates to the company's intellectual property rights and legal standing regarding its technology. This type of announcement, concerning the granting or denial of patents, falls under the category of legal proceedings or intellectual property matters. Since there is no specific code for 'Patent Grant Announcement,' and it details a significant legal/IP development, it is best classified as a Legal Proceedings Report (LTR) or potentially a general Regulatory Filing (RNS). Given the specific nature of patent acquisition, LTR is a strong fit, as patents are legal instruments. However, since the core event is the *granting* of a patent, which is a positive IP development, and not necessarily a lawsuit or regulatory action against the company, the most appropriate general category for significant, non-financial, non-management corporate news that doesn't fit elsewhere is often RNS (Regulatory Filings/Miscellaneous Announcements). Given the options, LTR covers legal matters, and RNS is the fallback. Since this is a specific announcement about a patent grant, which is a form of regulatory/legal approval, and it is not a standard financial report, RNS is the safest general classification for specific, non-standard corporate news, although LTR is plausible if interpreted broadly as a legal development. Given the context of IP protection, I will lean towards RNS as the most general fit for specific regulatory/legal milestones that aren't ongoing litigation.
2023-12-15 Polish
Skonsolidowany raport GK Scope Fluidics za III kwartał 2023 r.
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly financial report for Scope Fluidics S.A. covering the 9-month period ending September 30, 2023. It contains detailed consolidated and standalone financial statements (balance sheets, income statements, cash flow statements) and management commentary. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2023
2023-11-29 Polish
Współpraca z BIT w ramach projektu BacterOMIC - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is written in Polish and discusses a cooperation agreement between a subsidiary (Bacteromic) and a German company (BIT) regarding the production of 10 diagnostic devices related to the BacterOMIC project. It details the scope, timeline (Q1 2024 delivery), and estimated cost (approx. 600k EUR net). This announcement concerns a significant operational step, partnership, and potential commercialization effort related to a specific project, which falls under general business updates or regulatory disclosures. Since it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a specific capital event (CAP, SHA), it best fits the general category for regulatory announcements that do not have a more specific code. Given the context of a 'raport bieżący' (current report) detailing operational progress and partnership, and lacking a better fit among the specific codes (like M&A, DIV, DIRS), the most appropriate classification is the general regulatory filing fallback category.
2023-11-07 Polish
Raport biegłego rewidenta z przeglądu SF Scope Fluidics H1 2023
Audit Report / Information Classification · 1% confidence The document is titled "RAPORT NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z PRZEGLĄDU ŚRÓDROCZNEGO SKRÓCONEGO JEDNOSTKOWEGO SPRAWOZDANIA FINANSOWEGO SCOPE FLUIDICS S.A. OBEJMUJĄCEGO OKRES OD 1 STYCZNIA 2023 R. DO 30 CZERWCA 2023 R." (Independent Auditor's Review Report on the Interim Condensed Consolidated Financial Statements of Scope Fluidics S.A. for the period from January 1, 2023, to June 30, 2023). This explicitly describes a review of an interim (half-year) financial statement conducted by an external auditor. This aligns perfectly with the definition of an Audit Report / Information (AR), which covers standalone audit reports and results of internal/regulatory stress tests, distinguishing it from a full Annual Report (10-K) or a standard Interim Report (IR) which would be the company's own filing, not the auditor's review report on it. The content confirms it is a review report concluding that nothing came to the auditor's attention to suggest non-compliance with IAS 34 (Interim Financial Reporting). H1 2023
2023-10-02 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.